CURRICULUM VITAE CHRISTOPHER J. DESTACHE PERSONAL · CURRICULUM VITAE CHRISTOPHER J. DESTACHE PERSONAL ... Fletcher CV, Li Q. Topical ... Ahmad I, Zhao X, Parameswaran S,

CURRICULUM VITAE CHRISTOPHER J. DESTACHE

PERSONAL Home: 5211 South 166 Avenue Circle Omaha, Nebraska 68135 (402) 894-2834

Office: Creighton University School of Pharmacy and Health Professions

Department of Pharmacy Practice Omaha, Nebraska 68178 (402) 280-4744 [email protected] Professional Licensure: Nebraska License # 9813 1984 APhA Certified Immunization Specialist 2009 Basic Cardiac Life Support 2008-2016 SIDP Antimicrobial Stewardship Certificate 2014 EDUCATION American Association of Colleges of Pharmacy Academic Research Fellows Program Sabbatical Leave: The Center for Neurovirology and Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE

2013 – 2014 Jan – Aug 2002 Oct – Nov 1999

Completed Family Practice Pharmacy Fellowship, Creighton University Schools of Medicine and Pharmacy & Health Professions

July 1, 1984 - June 30, 1985

Graduated with Doctor of Pharmacy Degree Creighton University School of Pharmacy & Health Professions

1980 – 1984

PROFESSIONAL EMPLOYMENT Primary Appointment: Professor of Pharmacy Practice Creighton University School of Pharmacy & Health Professions Infectious Diseases Clinical Pharmacist Creighton University Medical Center Associate Professor of Pharmacy Practice, Creighton University School of Pharmacy & Health Professions

2006 - Present 1993 – Present 1995 – 2006

Curriculum Vitae for Christopher J. Destache, Pharm. D., FCCP

2

Rank and Tenure Granted April 1, 1995 Vice-Chair for Research, Department of Pharmacy Practice Creighton University School of Pharmacy & Health Professions

July 2004 – June 2015

Secondary Appointment: Professor of Infectious Diseases, Department of Internal Medicine, Creighton University School of Medicine

June 2011 - Present

Secondary Appointment: Professor of Medical Microbiology and Immunology, Creighton University School of Medicine Secondary Appointment: Associate Professor of Medical Microbiology and Immunology, Creighton University School of Medicine

2007 – Present 1997 – 2006

Residency Director Coordinator of the Creighton University School of Pharmacy & Health Professions/Saint Joseph Hospital Department of Pharmaceutical Services Pharmacy Practice Residency Program

2001 – 2002 1997 – 2002

Assistant Professor of Pharmacy Practice, Creighton University School of Pharmacy & Health Professions

1985 – 1995

Director of the Clinical Pharmacokinetic Service, Saint Joseph Hospital, Omaha, NE

1985 – 1993

PROFESSIONAL AFFILIATIONS American College of Clinical Pharmacy 1987-Present Infectious Diseases PRN 2000-Present Midwest College of Clinical Pharmacy 2006-Present Rho Chi National Honor Society 1987-Present American Society for Microbiology 1992-Present Society of Infectious Disease Pharmacists 1994-Present American Association of Colleges of Pharmacy 2006-Present American Society for Nanomedicine 2010-2011 Nebraska Center for Virology 2012-Present American Academy of HIV Medicine 2015-Present TEACHING EXPERIENCE Instructor of Record: PHA 586 Clinical Infectious Disease Clerkship 4 credit hour average 2-3 students/month for 6 months/year 1993-2015


3

Lecturer: PHA 415 Pharmacotherapeutics, 7 credit hour/semester. (Web and Campus) - Topic: Septic Shock 1991 - 2001 - Topic: Osteomyelitis 1991 - Present - Topic: Endocarditis 1992 – 2005; 2007-

Present - Topic: Central Nervous System Infections 1993 - Present - Topic: Tuberculosis 1997 - 2004 - Topic: Soft Tissue Infections 1994 - 2004 - Topic: Fungal Infections 1995 - 2004 - Topic: HIV Infection 1997 - Present - Topic: Introduction to Antimicrobial Therapy 1997 – Present - Topic: Bioterrorism 2002 Graduate courses: CTS 712 Applied Pharmacokinetics and Pharmacodynamics for the Clinician 2010 – 2011 MPS 793 Pharmaceutical Sciences Seminar Series 2015 MIC 753 Antimicrobial Agents and Chemotherapy Summer 2016 Co-Instructor of Record: NDP 461 Pharmacotherapeutics IV 1998 - 2014 Pharmacotherapeutics course for Non-Traditional Doctor of Pharmacy students dealing with Infectious Diseases topics. Lecturer: PHA 415 Clinical Case Studies relating Infectious Diseases to patients 1997 - Present Instructor of Record: PHA 464 Clinical Pharmacokinetics 1985 - 1996 Lecturer: PHA 464 Clinical Pharmacokinetics 1987 – 1998 Lecturer: NUR 606 Nursing Pharmacology Topic: Infectious Diseases 1997 – 2008 Topic: HIV and AIDS 1999 – 2008 Topic: Antimicrobials, antifungals, antivirals 2012 – Present


4

PUBLICATIONS Articles: Peer Reviewed

1. Mandal S, Prathipati PK, Pol G, Destache CJ. Plasma and tissue pharmacokinetics of two dosages of tenofovir+elvitegravir nanoparticles from Hu-NSG mice. (In Preparation).

2. Destache CJ, Guervil DJ Vazquez JA, Kaye KS. Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience. (In Preparation).

3. Mandal S, Kang G, Zhe Y, Prathipati PK, Li Q, Destache CJ. Combination antiretroviral nanoparticles as a sustained treatment modality in humanized mice. Proceedings of the National Academy of Sciences USA 2016 (In Preparation).

4. Ased S, Rayes H, Dhami J, Amosson N, Fordjour A, Macaraen J, Vivekanandan R, Wilson J, Cabri A, Davids M, Anthone J, Cavaleri SA, Destache CJ. Evaluation of Staphylococcus aureus Bacteremia: Academic and Community-based Management Within a Health System Clin Infect Dis 2016 (In Preparation).

5. Mandal S, Prathipati PK, Kang G, Zhao Y, Zhe Y, Fan W, Li Q, Destache CJ. Tenofovir alafenamide and elvitegravir nanoparticles for long-acting prevention of HIV-1 vaginal transmission. AIDS 2016 Submitted.

6. Mandal S, Belshan MB, Zhou Y, Destache CJ. An enhanced emtricitabine loaded long-acting nano-formulation for prevention or treatment of HIV infection Antimicrob Agents Chemother 2016 Submitted.

7. Destache CJ. HIV cure. iScience 2016 Accepted. 8. Foral P, Anthone J, Destache C, Vivekanandan R, Preheim L, Gorby G, Horne J,

Dobronski L, Syed J, Mindru C, Ali M, Ali K, Neemann K, Bittner M. Interprofessional team practice education and face-to-face communication techniques in antimicrobial stewardship programs at two academic medical centers. J Am Osteo Assoc 2016;116(9):588-93. doi: 10.7556/jaoa.2016.116.

9. Prathipati PK, Mandal S, Destache CJ. Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir, and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study. J Pharm and Biomed Anal http://dx.doi.org/10.1016/j.jpba.2016.07.040

10. Destache CJ, Mandal S, Date AA, Yuan Z, Kang G, Lu W, Shibata A, Bruck P, Zhao Y, Fletcher CV, Li Q. Topical application of tenofovir DF nanoparticles prevents HIV-1 vaginal transmission in humanized-BLT mice. Antimicrob Agents Chemother 2016; doi:10.1128/AAC.00450-16.

11. Narayanan MA, Haddad TM, Baskaran J, Reddy AK, Mansour G, Destache C, Mooss A, Wichman T, Morrow L, Suri R, Kalil AC, Vivekanandan R. Evidence of lower mortality in early surgical intervention for infective endocarditis: A meta-analysis. Heart 2016 Feb 11. pii: heartjnl-2015-308589. doi: 10.1136/heartjnl-2015-308589. [Epub ahead of print]

12. Date AD, Destache CJ. Natural polyphenols: Potential in the prevention of sexually transmitted viral infections. Drug Discovery Today 2015 Nov 4 pii: S1359-6446(15)00416-X. doi: 10.1016/j.drudis.2015.10.019. [Epub ahead of print].


5

13. Bossou AR, Castillo S, O’Brien KK, Opere CA, Destache CJ. Preventive HIV vaccines: Progress and challenges. US Pharmacist 2015;40(10):46-50.

14. Kovarova M, Council OD, Date AA, Long J, Nochii T, Belshan M, Shibata A, Vincent H, Baker CE, Thayer WO, Kraus G, Lachaud-Durand S, Williams P, Destache CJ, Garcia JV. Nanoformulations of rilpivirine for topical pericoital and systemic coital-independent administration efficiently prevent HIV transmission. PLoS Pathogen 2015;11:e1005075. PMCID 4536200.

15. Mandal S, Zhou Y, Shibata A, Destache CJ. Confocal fluorescence microscopy: an ultra-sensitive tool used to evaluate intracellular antiretroviral nano-drug delivery in HeLa cells. AIP Advances. 2015;5(8):084803. PMCID 4499042

16. Li Q, Tso FY, Kang G, Fan W, Lu W, Li Y, Yuan Z, Destache CJ, Wood C. Early antiretroviral therapy prevents the establishment of HIV-1 infection in humanized-BLT mice. JAIDS 2015;69:519-527. PMCID 4503390

17. Ahmad I, Zhao X, Parameswaran S, Destache CJ, Rodriguez-Sierra J, Ahmad H, Sorrentino J, Balasubramanian S. Direct differentiation of adult ocular progenitors into striatal dopaminergic neurons. International J Stem Cells 2015;8:106-111. PMCID 4445705

18. Au T, Destache CJ, Vivekanandan R. Hepatitis C: Looking toward interferon-sparing regimens. J Am Pharm Assoc 2015;55:e72-86. doi: 10.1331/JAPhA.2015.15508.

19. Date AA, Shibata A, McMullen E, La Bruzzo K, Bruck P, Belshan M, Zhao Y, Destache CJ. Thermosensitive gel containing cellulose acetate phthalate-efavirenz nanoparticles for prevention of HIV-1 infection. J Biomed Nanotech 2015;11:416-427.

20. Date AA, Shibata A, Bruck P, Destache CJ. Development and validation of a simple isocratic reverse-phase HPLC method for the determination of rilpivirine from tablets, nanoparticles, and cell lysates. Biomed Chromatog 2014 DOI 10.1002/bmc.3346. PMCID4391993

21. Destache CJ. Aminoglycoside-induced nephrotoxicity – A focus on monitoring: A review of the literature. J Pharm Pract 2014;27:562-66. doi: 10.1177/0897190014546102. Epub 2014 May 7.

22. DePestel DD, Eiland E III, Lusardi K, Destache CJ, Claude-Mercier R, McDaneld, P Lamp KC, Chung TJ, Hermsen ED. Assessing appropriateness of antimicrobial therapy: In the eye of the interpreter. Clin Infect Dis 2014 2014;59(Suppl 3):S154-S161.

23. Hermsen ED, McDaneld P, Eiland E III, Destache CJ, Lusardi K, Estrada S, Mercier R-C, DePestel D Lamp K, Anderson E, Chung T, McKinnon P. Breaking down the barriers: challenges with development and implementation of an industry-sponsored antimicrobial stewardship data collection and analysis tool. Clin Infect Dis 2014 2014;59(Suppl 3): S179-S184.

24. Dull RB, Friedman SK, Risoldi AM, Destache CJ. A systemic review of antimicrobial use for asymptomatic bacteriuria in non-catheterized adults. Pharmacother 2014; doi: 10/1002/phar.1437.

25. Date A and Destache CJ. A review of nanotechnological approaches for the prophylaxis


6

of HIV/AIDS. Biomaterials 2013;29:746-759. PMCID3761805. 26. Shibata A, McMullen E, Pham A, Belshan MA, Sanford B, Zhao Y, Goede M, Date A,

Destache CJ. Polymeric nanoparticles containing combination antiretroviral drugs for HIV-1 treatment. AIDS Res Hum Retrovir 2013;29(5):746-754. PMCID3636590

27. Knaak E, Cavalieri SM, Elsasser GN, Gonitzke A, Preheim LC, Destache CJ. Does antibiotic de-escalation for nosocomial pneumonia impact intensive care unit length of stay? Inf Dis Clin Pract 2013;21:172-176.

28. Date AA, Shibata A, Goede M, Sanford B, La Bruzzo K, Belshan M, Destache CJ. Development and evaluation of a thermosensitive vaginal gel containing raltegravir + efavirenz loaded nanoparticles for HIV prophylaxis. Antiviral Res 2012;96(3):430-436. PMCID 3513487

29. Teply R, Goodman M, Destache CJ. Lopinavir-ritonavir: A review for 2011. Clinical Medicine Insights 2011;3:93-102.

30. Destache CJ, Goede M, Belgum T. Antiretroviral nanoparticles: An extended drug delivery modality. Spotlight article. Therapeutic Delivery. 2010;1:383-386.

31. Destache CJ, Goede M, Belgum T, Shibata A, Belshan MA. Pharmacokinetics of antiretroviral release from PLGA nanoparticles in mice. J Antimicrob Chemother 2010;65:2183-2187. PMCID 2941676

32. Packard KA, Lenz TL, Destache CJ. Teaching heart failure treatment guidelines and assessing heart failure therapy. J Am J Pharm Educ 2010;74:Article 103. PMCID 2933012

33. Elsasser GN, Kavan M, Westerman GH, Destache CJ, Sexson E, Turner PD. Pharmacy student experiences with gambling. Am J Pharm Educ 2010;74:Article 18. PMCID2856415

34. Zhao M, Destache CJ, Ohia SE, Opere CA. Role of prostanoid production and receptors in the regulation of retinal endogenous amino acid neurotransmitters by 8-isoprostaglandin E(2), ex vivo. Neurochem Res 2009;34:2170-80.

35. Destache CJ, Belgum T, Christensen K, Shibata A, Sharma A, Dash AK. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect Dis 2009;9:198. PMCID2807870

36. Stading J, Herrmann J, Walters R, Destache C, Chock A. The impact of pharmacist intervention on diabetes patients in an ambulatory setting. Diabetes Spectrum 2009;22:241-246.

37. Dou H, Grotepas CB, McMillan JM, Destache CJ, Chaubal M, Werling J, James K, Rabinow B, Gendelman HE. Macrophage delivery of nanoformulated anti-retroviral drug to brain in a murine model of neuroAIDS. J Immunol 2009; 183:661-669. PMCID2765254

38. Nystrom K, Foral P, Davis E, Christensen C, Destache CJ. Rotation students’ perceptions of clinical workload documentation using a personal digital assistant. Hosp Pharm 2009;44:968-973.


7

39. Elsasser GN, Hoie E, Destache CJ, Monaghan MS. Availability of internet download lecture audio files on class attendance and examination performance. Int J Instruct Tech & Distance Learning 2009;6:Article 3.

40. Davis EM, Bebee A, Crawford L, Destache C. Nurse satisfaction using insulin pens in hospitalized patients. Diabetes Educator 2009;Jul 24 [Epub ahead of print].

41. Zhao M, Destache CJ, Zhan G, Liu H, Zhang Y, Govindarajan V, Opere CA. Regulation of endogenous amino acid neurotransmitters by isoprostanes in mammalian retina, ex vivo. Methods and Findings in Experimental and Clinical Pharmacology 2008;30:615-26.

42. Skrabal MZ, Jones RM, Nemire RE, Boyle CJ, Assemi M, Kahaleh AA, Soltis DA, Allen RE, Hritcko PM, O’Sullivan TA, Destache CJ. National survey of volunteer pharmacy preceptors. Am J Pharm Educ 2008;72:112. PMCID2630137

43. Davis EM, Christensen C, Nystrom K, Foral P, Destache CJ. Patient satisfaction and cost associated with insulin administered by pen device or syringe during hospitalization. Am J Hosp Pharm 2008;65:1347-1357.

44. Turaga K, Wright A, Lee R, Dias WP, Destache C, Christian R, Fitzgibbons RJ Jr. A randomized trial of the peri-operative use of COX-2 inhibitors in Lichtenstein herniorrhaphy. Hernia 2008;12:515-519.

45. Elssaser GN, Goodman MD, Destache CJ, Frey DR, Hadi Z. Preprinted risk assessment and prophylaxis order form for venous thromboembolism. Am J Heath Syst Pharm 2007;64:1294-1298.

46. Dou H, Morehead J, Destache CJ, Kingsley JD, Skyakhtenko L, Zhou U, Chaubal M, Werling J, Kipp J, Rabinow B, Gendelman HE. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virol 2007;358(1): 148-158.

47. Kingsley JD, Dou H, Morehead J, Gorantla S, Rabinow B, Gendelman HE, Destache CJ. Nanotechnology: A focus on nanoparticles as a drug delivery system. J Neuroimmun Pharmacol 2006;1:340-350.

48. Gorantla S, Dou H, Boska M, Destache CJ, Nelson J, Poluektova L, Rabinow B, Gendelman HE, Mosley RL. Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. J Leuko Biol 2006;80(5):1165-1174.

49. Dou H, Destache CJ, Morehead JR, Mosley RL, Boska MD, Kingsley J, Gorantla S, Poluektova L, Nelson JA, Chaubal M, Werling J, Kipp J, Rabinow B, Gendelman HE. Development of a macrophage-based nanoparticle platform for anti-retroviral drug delivery. Blood 2006;108(8);2857-2835. PMCID1895582

50. Enose Y, Destache CJ, Mack AL Anderson JL, Ullrich F, Ciborowski P, Gendelman HE. Proteomic fingerprints distinguish microglia, bone marrow, and spleen macrophage populations. Glia 2005;51(3):161-172.

51. Boska MD, Lewis TB, Destache CJ, Benner EJ, Nelson J, Uberti M, Mosley RL, Gendelman HE. Quantitative 1H magnetic resonance spectroscopic imaging determines


8

therapeutic immunization in an animal model of Parkinson’s disease. J Neurosci 2005; 25(7):1691-1700.

52. Benner EJ, Mosley RL, Destache CJ, Lewis TB, Jackson-Lewis V, Gorantla S, Nemechek CR, Green SR, Przedborski S, and Gendelman HE. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson’s disease. Proc Nat Acad Sci USA 2004;101:9435-9440. PMCID438994

53. Carlson KA, Ciborowski P, Schellpeper CN, Biskup TM, Shen R-F, Luo X, Destache CJ, Gendelman HE. Proteomic fingerprinting of HIV-1-infected monocyte-derived macrophages: A preliminary report. J Neuroimmunology 2004;147:35-42.

54. Gendelman HE, Destache CJ, Zelivyanskaya ML, Nelson JA, Boska MD, Biskup TM, McCarthy MK, Carlson KA, Nemechek CR, Benner EJ, Mosley RL. neuroimaging and proteomic tracking of neurodegeneration in MPTP-treated mice. Annuals of the New York Academy of Sciences 2003;991:319-321.

55. Packard KA, Backes JM, Lenz TL, Wurderman RL, Destache CJ, Hilleman DE. Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. Pharmacother 2002;22:1527-1532.

56. Chock A, Gong V, Destache CJ. Antibacterials and Acute Exacerbation of Chronic Bronchitis: Issues for Formulary Decision-Makers. Disease Management and Health Outcomes 2002;10:333-336.

57. Destache CJ. Optimizing Economic Outcomes in Acute Exacerbations of Chronic Bronchitis. Pharmacother 2002;22 (Supple):S44-S48.

58. Pong A, Harrison CJ, Seidel TW, Needelman HW, Jirka JH, Awad KA, Cothran DL, Ohri L, Destache CJ. Pilot study using a nomogram to predict gentamicin dosing intervals in preterm neonates treated with high dose gentamicin. The Journal of Pediatric Pharmacology and Therapeutics 2001;6:392-400.

59. Faulkner MA, Hilleman DE, Destache CJ, Mooss AN. Potential influence of the timing of LDL-cholesterol evaluation in patients with acute coronary syndromes. Pharmacother 2001;21:1055-1060.

60. Ayca B, Izzettin FV, Pala O, Destache CJ, Stohs SJ, Uras F. Comparison of Biochemical Parameters in Pediatric Patients with and without Urinary Tract Infection. The Internet Medical Journal 2001. http://www.medjournal.com.

61. Kelly JJ, Horowitz EA, Destache CJ, Fruin AH, Long VA. Diagnosis and treatment of complicated tubercular meningitis. Invited publication to Neurology Review Series 2001;2:6-7,24.

62. Destache CJ, Pakiz CB, Larsen C, Owens HM, Dash AK. Penetration of Levofloxacin into the Cerebrospinal Fluid and its Pharmacokinetics in an Experimental Rabbit Meningitis Model. J Antimicrob Chemother 2001;47:611-615.

63. Streetman DS, Nafziger AN, Destache CJ, Bertino JS, Jr. Individualized Pharmacokinetic Monitoring Results in Less Aminoglycoside-Associated Nephrotoxicity. Pharmacother 2001;21:443-451.

64. Alsarif NZ, Destache CJ, Roche VF. Teaching Medicinal Chemistry to Meet Outcome


9

Objectives for Pharmacy Students. Pharm Education (Chinese). 2000;3 (Fall):50-53. 65. Kelly JJ, Destache CJ, Horowitz EA, Fruin AH, Long VA. A Complicated Case of M.

tuberculosis Meningitis: Diagnosis and Treatment. Pharmacother 1999;19:1167-1172. 66. Destache CJ, Dewan N, O’Donohue, Jr. W, Campbell JC, Angellio VA. Economic and

Clinical Effects of Treating Acute Exacerbations of Chronic Bronchitis. J Antimicrob Chemother 1999;43(Suppl A):107-113.

67. Owens H, Destache CJ, Dash AK. Simple Liquid Chromatographic Method of the Blood-Brain Barrier Permeability Characteristics of Ceftriaxone in an Experimental Rabbit Meningitis Model. J Chromatography B 1999;728(1):97-105.

68. Alsarif NZ, Destache CJ, Roche VF. Teaching Medicinal Chemistry to Meet Outcome Objectives for Pharmacy Students. Am J Pharm Educ 1999;63 (Spring):34-40.

69. Destache CJ, Pakiz CB, Dash AK, Larsen C. Nitric Oxide Concentrations in S. pneumoniae Meningitis: Correlation to Cytopathology. Pharmacother 1998;18:628-634.

70. Elsasser GN, Goodman M, Destache CJ. Drug Interactions with Protease Inhibitors. US Pharmacist 1998;March:52-62.

71. Destache CJ, Pakiz CB, Kersting K. Effect of Bovine Cerebrospinal Fluid on the Microbiological Killing of Azithromycin against N. meningitidis, S. pneumoniae, and H. influenzae. Pharmacother 1997;17:989-992.

72. Destache CJ, Pakiz CB, Stoysich AM. A-80556 for S. pneumoniae Meningitis using Microdialysis: Pharmacodynamics and Pharmacokinetics. J Antimicrob Chemother 1996;38:977-985.

73. Sanders CC and Destache CJ. β-Lactamase Resistance. US Pharmacist 1996; July (Suppl): 1-12.

74. Destache CJ. Clinical and Economic Benefits of a Clinical Pharmacokinetic Service: 1987 Versus 1992 Data. Medical Interface 1994;7(11):84-90.

75. Bertino JM, Rodvold K, Destache CJ. Cost-Benefit of a Clinical Pharmacokinetic Service. Clin Pharmacokin 1994;26:641-651.

76. Destache CJ. The Use of Therapeutic Drug Monitoring in Pharmacoeconomics. Ther Drug Monitor 1993;15:608-610.

77. Destache CJ. Cost-Benefit Relationships in the Use of a Pharmacokinetic Service. PharmacoEcon 1993;3:433-436.

78. Massoomi F, Mathews HG, Destache CJ. Effect of Seven Fluoroquinolones on the Determination of Creatinine by the Picric Acid and Enzymatic Methods. Annals of Pharmacother 1993;27:586-588.

79. Massoomi F, Savage JL, Destache CJ. Omeprazole - A Comprehensive Review. Pharmacother 1993;13:46-59.

80. Kosirog J, Rospond RM, Destache CJ, Hall PD. Aminoglycoside Forecasting in Neutropenic Patients with Cancer. Clin Pharmacokinet 1993;24:79-87.

81. Hilleman DE, Mohiuddin SM, Destache CJ, Stoysich AS, Nipper HC, Maleskar MA.


10

Impact of Food on the Bioavailability of Encainide. J Clin Pharmacol 1992;32:833-837. 82. Destache CJ, Hilleman DE, Mohiuddin SM, Lang PT. Predictive Performance of

Bayesian and Nonlinear Least Squared Regression for Lidocaine. Ther Drug Monit 1992;14:286-291.

83. Hilleman DE, Mohiuddin SM, Mooss A, Hunter CB, Destache CJ, Sketch MH, Sr. Comparative Pharmacodynamic of Intravenous Lidocaine in Acute and Chronic Ventricular Arrhythmias. Annuals of Pharmacother 1992;26:763-767.

84. Destache CJ. Pharmacoeconomics. Frontiers in Therapeutic Drug Monitoring and Clinical Toxicology 1992; (Suppl Issue) 28-30.

85. Mohiuddin SM, Stoysich AS, Destache CJ, Gannon JM, Hilleman DE, Sketch MH. Cost-Effectiveness of Early versus Late Initiation of Warfarin during Heparin Therapy. Am Heart J 1992;123:729-732.

86. Stoysich AS, Mohiuddin SM, Destache CJ, Nipper HC, Hilleman DE. Influence of Mexiletine on the Pharmacokinetics of Theophylline in Healthy Volunteers. J Clin Pharmacol 1991;31:354-357.

87. Malesker MA, Mohiuddin SM, Destache CJ, Stoysich AS, Dean RR, Hilleman DE, Sketch MS. Pharmacokinetic and Tolerance Evaluation of Actisomide, A New Antiarrhythmic Agent in Healthy Volunteers. DICP The Annuals of Pharmacother 1991;25:231-233.

88. Destache CJ, Meyer SM, Bittner MB, Hermann KG. Impact of a Clinical Pharmacokinetic Service on Patients Treated with Aminoglycosides: A Cost-Benefit Analysis. Ther Drug Monit 1990;12:419-426.

89. Destache CJ, Meyer SM, Rowley KA. Does Accepting Pharmacokinetic Recommendations Impact Length of Hospitalization? A Cost-Benefit Analysis. Ther Drug Monit 1990;12:427-433.

90. Destache CJ, Meyer SM, Ortmeier BG, Padomek MT. Impact of a Clinical Pharmacokinetic Service on Patients Treated with Aminoglycosides for Gram-Negative Infections. DICP The Annuals of Pharmacother 1989;23:33-37.

91. Hilleman DE, Mohiuddin SM, Patterson AJ, Ortmeier BG, Destache CJ. Comparative Bioequivalence and Efficacy of Two Sustained-Release Procainamide Formulations in Patients with Cardiac Arrhythmias. Drug Intell Clin Pharm 1988;22:554-558.

92. Meyer SM, Destache CJ, Brittan J, Gurnee M, Barone EJ. A Pharmacy Fellowship in a Family Practice Training Program. Family Med 1986;18:394-396.

93. Hilleman DE, Mohiuddin SM, Destache CJ. Lidocaine-Induced Second Degree Mobitz Type II Heart Block: A Case Report and a Review of the Literature. Drug Intell Clin Pharm 1985;19:669-673.

RESEARCH

Principle Investigator: 1. Long-acting combination antiretroviral nanoparticles for treatment of SIV. NIAID 2016-


11

2020. $1,900,312 Not funded. 2. R01AI117740-01 (Destache) 02/01/2015 – 01/30/2019 3.0 calendar mon

NIAID $308,705 Long-acting antiretroviral nanoparticles for HIV prophylaxis.

The goal for this project is to evaluate several antiretroviral drugs incorporated into a nanoparticle formulation for HIV prevention in a Hu-BLT mouse model.

3. Acute bacterial skin and skin structure infection (abSSSI) practice pattern assessment (DUR000501). Durata Therapeutics. $5,215 Funded. 2014-2015.

4. Evaluation of nanomedicines in the treatment of HIV. National Institute of Allergy & Infectious Diseases (NIAID) $434,988 2014-2016. Not funded.

5. Combination antiretroviral nanoparticles for HIV prophylaxis. National Institute of Allergy & Infectious Diseases (NIAID) $2,315,482 2014-2018. Not Funded.

6. Use of thermosensitive gel-based tenofovir nanoparticles in a humanized BLT mouse model for HIV prevention. Nebraska Center for Virology Award $50,000/year. 2013-2015. Funded.

7. Combination antiretroviral nanoparticles for treatment in a humanized mouse model of HIV. Nebraska Smoking Tax Fund (LB692) sponsored by Creighton University. $74,850 2013-2014 Funded.

8. Thermosensitive gel containing antiretroviral nanoparticles for HIV prophylaxis. National Institute of Allergy & Infectious Diseases (NIAID) $2,743,286 2013-2017 Not funded.

9. R56AI095115-01 (Destache) 09/01/2011-08/30/2013 2.5 calendar mon NIAID $308,800 Once monthly antiretroviral nanoparticles for HIV-1 treatment. The goal of this project was to evaluate antiretroviral drugs incorporated into a nanoparticle formulation for HIV treatment in a Hu-BLT mouse model.

10. Efficacy of combination antiretroviral nanoparticles in a mouse model of HIV-1. Clinical and Translational Research Grant Program, Creighton University $37,500 2011-2012 Funded.

11. Once Monthly Antiretroviral Nanoparticles for HIV-1 Treatment. National Institute of Allergy and Infectious Diseases, National Institutes of Health $2,330,638 2011-2015. Not Funded.

12. Clinical Assessment Program and Teflaro Utilization Registry (CAPTURE). A multicenter, retrospective cohort study to characterize the use of Teflaro in the treatment of patients with acute bacterial skin and skin structure infection or community-acquired pneumonia. Cerexa, Inc. Funded. 2012-2015.

13. MRI-R2: Acquisition of atomic force microscopy for School of Pharmacy. National Science Foundation. $987,280 2010-2013. Not Funded.

14. 3R15AI076039-01A1S1 (Destache) 01/03/2010-01/02/2011 NIAID $86,000 Pharmacology of Antiretroviral Nanoparticle Micelles The goal of this project was to investigate the use of a hollow-fiber system to evaluate the


12

pharmacokinetics of antiretroviral nanoparticles. 15. 1R15AI076039-01A1 (Destache) 09/01/2008-08/30/2010 2.5 calendar mon

NIAID $150,000 Pharmacology of Antiretroviral Nanoparticle Micelles. The goal of this project was to determine the physical-chemical properties and pharmacokinetics of antiretroviral nanoparticles in mice.

16. Creighton Pharmacogenomics Core Laboratory. LB692 Tobacco Settlements for Biomedical Research. $854,870 2004-2007. Not Funded.

17. GDNF Nanotechnology for Neuroprotection. School of Pharmacy Faculty Development Fund. $14,690 2004-2006 Funded.

18. Human Recombinant Glial Cell-Derived Neurotrophic Factor Nanoparticles. Health Futures Foundation. $19,850 2004-2006. Not Funded.

19. The Effect of MPTP on Proteasome Subunits in C57BL6 Mice Compare to Human a-Synuclein Transgenic Mice. Health Futures Foundation $20,000 2003-2005, Not Funded.

20. Acute Exacerbation of Chronic Bronchitis: Hospitalization due to Patient-Specific Factors or Antibiotic Resistant Pathogen? Personal funding. 2001-2002.

21. CSF Penetration of Daptomycin in a Rabbit Model of Pneumococcal Meningitis. Funded by Cubist Pharmaceuticals $7,142.40. 2001-2002.

22. Pharmacokinetics and CSF Penetration of Levofloxacin in an Experimental Rabbit Meningitis Model with Penicillin Sensitive Pneumococcus. Funded by Ortho-McNeil Pharmaceuticals $48,850.60 1998-1999.

23. Azithromycin Efficacy using Simulated IV Azithromycin Concentrations Against Respiratory Pathogens. Funded by Pfizer Pharmaceuticals $24,650. 1997-1998.

24. Nitric Oxide Concentrations in S. pneumoniae Meningitis: Correlation to Cytopathology. Funded by the American College of Clinical Pharmacy Research Award $10,000 1996-1997

25. Nitric Oxide Concentrations in S. pneumoniae Meningitis: Correlation to Cytopathology. Funded by the Society of Infectious Diseases Pharmacists $14,950 1996-1997

26. Effect of 10% Human Serum on the Microbiological Killing of Azithromycin against S. pneumoniae, N. meningitidis, and H. influenzae. Funded by Pfizer Pharmaceuticals, Inc. $17,089.00 1996-1997.

27. Efficacy and Costs of Antimicrobials Used in the Treatment of Otitis Media. Funded by Pfizer Pharmaceuticals. $12,000.00 1995-1996

28. Effect of Pooled Bovine Cerebrospinal Fluid on the Activity of Azithromycin against Bacterial Meningitis Organisms. Funded by Pfizer Pharmaceuticals. $15,201.44 1995-1996.

29. Cost-Benefit of Antimicrobial Agents in the Treatment of Intra-Abdominal Infections. Funded by Pfizer Pharmaceuticals, Inc. $22,049.82 1995-1996.

30. A-80556 for S. pneumoniae Meningitis using Microdialysis: Pharmacodynamics and Pharmacokinetics. Funded by Abbott Laboratories $ 4,267.20 1994.


13

31. Cost of Treatment for Community-Acquired Pneumonia with Intravenous Ceftriaxone and Oral Cefpodoxime: A Concurrent Review. Funded by The Upjohn Co. $ 7,930.50 1993-1994.

32. Cost of Treating Acute Exacerbation of Chronic Bronchitis with Ciprofloxacin or Cefaclor: A Retrospective Comparison. Funded by Bayer Pharmaceuticals, Inc. $ 14,680.68 1993-1994.

33. Validation of Cost-Benefit of a Clinical Pharmacokinetic Service: 1986 vs. 1992 Data. Funded by Abbott Laboratories $ 26,113.16 1993-1994.

34. Comparison of Outpatient Treatment of Community-Acquired Pneumonia: Cefaclor vs. Azithromycin. Funded by Pfizer, Inc. $11,526.00 1993-1994.

35. Development grant from Ciba-Corning Diagnostics Division $5,000 1992. 36. A Comparison of Theophylline Levels by the Abbott TDX and Biotrack 516 Systems.

Funded by Ciba-Corning Diagnostics, Inc. $4,360 1992. 37. Assessment of Risk Factors for Aminoglycoside-Induced Nephrotoxicity. Funded by the

Upjohn Company, Pharmacy Science Liaison $2,000. 1990. 38. Interaction Between Steady-State Diltiazem with a Single Dose of Warfarin in Normal

Volunteers. Biomedical Science Research Grant $2,000 1989. 39. Impact of a Clinical Pharmacokinetic Service on Patients Treated with Aminoglycosides:

A Cost-Benefit Analysis. Funded by the Upjohn Company, Pharmacy Science Liaison $3,235 1987.

40. Monitoring Outpatient Serum Theophylline Concentrations: A Method of Cost Containment. Funded by The Family Health Foundation of America $2,800 1985-1986.

Co-Principle Investigator: 1. EPSCoR Major Instrument Grant. Dr. E. Jeffrey North co-principle investigator. National

Science Fountation. $472,372 2016-2020.

2. Combined nanofabrications for antiretroviral prophylaxis. Dr. Annemarie Shibata co-principle investigator. President’s Faculty Research Fund. Creighton University $15,000 2012-2013.

3. An Open-label Randomized Comparison of the Efficacy, Safety, Treatment Outcomes and Total Costs of IV Zosyn to those of IV Unasyn plus Gentamicin for the treatment of patients with community acquired infections due to complicated appendicitis. Dr Robert Fitzgibbons, Jr.co-principle investigator. Wyeth-Ayerst Laboratories $35,000 1997-1999.

4. Evaluation of Betafectin in the Prevention of Intra-Abdominal Infection for Patients at High-Risk Undergoing Major Intra-Abdominal Surgery. Dr. Robert Fitzgibbons, Jr. co-principle investigator. Alpha Beta Technology, Inc. $59,520 1995-1996.

5. Pharmacokinetic Evaluation of SCH 29851 in Volunteers with Alcoholic Liver Disease. Dr. Syed Mohiuddin co-principle investigator. Schering-Plough Corporation, $46,410 1987.

Co-Investigator:


14

1. 1R15 AI118550-01 (Shibata A) 04/01/2015-03/30/2017 0.06 calendar mon NIAID $300,000 Integrase inhibitor combination nanomicrobicide for prevention of HIV infection. The goal of this project is to evaluate dolutegravir+cellulose acetate phalate for HIV prevention as a vaginal gel.

2. Eradication of HIV-1 brain reservoirs in the BLT-mouse model. Charles Wood, Ph. D. principle investigator. $3,670,661 NAID 2014-2019. Not funded.

3. Protease inhibitor modifications for oral sustained delivery. Abhijit Date, Ph. D. principle investigator. $143,000 NIAID 2013-2015. Not funded.

4. NNRTI-based nanoparticles in a vaginal gel for HIV prevention. Annemarie Shibata, Ph. D. principle investigator. $385,420. NIAID 2013-2015. Not funded.

5. Determination of the Efficacy of Nanoparticle driven Antiretroviral Drug Delivery Systems using Cellular Model Systems. Annemarie Shibata, Ph. D., principle investigator. $10,000 CU President’s Faculty Research Fund. 2011-2012. Funded.

6. Clinical and economic impact associated with agents used for treatment of suspected or documented infections due to methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and Pseudomonas aeruginosa. Cubist Pharmaceuticals, Inc. Funded. 2012-2013.

7. Warfarin Dosing: Pharmacogenetic Algorithm Compared to Pharmacist Dosing. Angie Goeser, Pharm. D. principle investigator. American College of Clinical Pharmacy Foundation. $20,000 2006-2007. 20% effort. CU Internal Funding $4,000.

8. Novel Nanodelivery System for Cancer Treatment. Alekha Dash, Ph. D. principle investigator. Cancer & Smoking Research Program (LB595). $240,000 2006-2009 20% effort. Not Funded.

9. Nebraska Center for Drug Delivery and Nanomedicine (CDDN). Alexander Kabanov, D. Sc., Ph. D. principle investigator. COBRE. National Institute of Health $12,500,000 2005-2010. 20% effort Project 4. Not Funded.

10. Nebraska Center for Nanomedicine (NCN). Alexander Kabanov, D. Sc., Ph. D. principle investigator. COBRE. National Institute of Health $11,500,000 2004-2009. 25% effort Project 2. Not Funded.

11. Mosley RL, Destache CJ, Przedborski S, Lewis T, Gendelman HE. COP-1 as an Immune-Mediated Neuroprotectant for Parkinson’s Disease. 20% effort. R. Lee Mosley, Ph. D. principle investigator. National Institute of Health 5 R21 NS049264 $250,000 2004-2006. Funded.

12. Efficacy of Indinavir Nanoparticles in a Blood Brain Barrier Model of HIV. Jenae Limoges, M. D. principle investigator. Baxter Pharmaceuticals, Inc. $40,000. 25% effort. 2004.

13. Lenz TL, Arouni AA, Hilleman DE, Faulkner MA, Destache CJ. Pharmacokinetic interaction between warfarin and ginseng. 2002 American College of Clinical Pharmacy-AstraZeneca Cardiovascular Research Award, July 1, 2002 – June 30, 2003, $10,000.


15

14. Establishment of a Chemically-Induced Neurodegenerative Mouse Model System for the Study of Autoimmune Neuroprotection. R. Lee Mosley, Ph. D. principle investigator. Pfizer, Inc. $40,000 2003.

15. Therapeutic Vaccination Strategy for Amyotrophic Lateral Sclerosis. Serge Przedborski, Ph. D. principle investigator. NINDS, NIH $40,000 2003-2006.

16. SPECT Evaluation of GBR 12909 Inhibition of β-CIT/dopamine transporter (DAT) interactions. Pfizer, Inc. $30,000 2003.

17. Immune-mediated protection of dopaminergic neurodegeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson’s disease. Dr. R. Lee Mosley, principle investigator. Michael J. Fox Foundation $167,546 7/1/03 – 6/30/05. 20% effort. Not Funded.

18. Parkinson’s Disease Research. Dr. Howard E. Gendelman, principle investigator. University of Nebraska Medical Center $160,000 2002 - 2004.

19. Vioxx vs. Placebo for Pain Control in Ingunial Hernia Surgery. Dr. Robert Fitzgibbons, Jr., principle investigator. Merck Pharmaceuticals. 2001-2003.

20. Multicenter Study to Evaluate the Safety and Efficacy of Levofloxacin 500 mg , Once Daily, in the Treatment of Community Acquired Pneumonia in Adults. Dr. David Dworzack, principle investigator. Ortho-McNeil Pharmaceuticals $10,000 1997-1999.

21. Alternative Dosing of Gentamicin in Neonates. Christopher J. Harrison, M. D. Principle Investigator. Center for the Study of Children’s Issues, Creighton University. $1,000 1997-1998.

22. Randomized Placebo-Controlled Trial of MAK 915F in Sepsis with Hyperinflammatory Response. Dr. Edward Horowitz principle investigator. Knoll Pharmaceutical Co. $ 45,000 1995-1997.

23. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Filgrastim in the Treatment of Patients with Pneumonia and Severe Sepsis or Septic Shock. Dr. David Dworzack principle investigator. Amgen, Inc. $67,500 1995-1998.

24. Randomized Study to Determine the Safety and Efficacy of oral Levofloxacin Compared with Amoxicillin-Clavulanate potassium in the Treatment of Acute Sinusitis in Adults. Drs. David Chait and David Dworzack co-principle investigators. R.W. Johnson Pharmaceutical Research Institute. $40,000 1993-1994.

25. A Double-Blind Placebo-Controlled Study to Determine Whether Procrit can Reduce Peri-Operative Transfusion Requirements in Patients Undergoing Major Orthopedic Surgery. Dr. Michael McGuire principle investigator. R.W. Johnson Pharmaceutical Research Institute. $50,200 1993-1994.

26. Double-Blind Placebo-Controlled Study to Determine Efficacy and Safety of G-CSF in Moderate to Severe Community Acquired Pneumonia. Dr. David Dworzack principle investigator. Amgen, Inc. $70,000 1993-1995.

27. A Randomized Study to Evaluate the Effects of Multiple Doses of Ofloxacin and Ciprofloxacin on Theophylline Levels in Subjects with Chronic Obstructive Pulmonary


16

Disease. Dr. Walter J. O’Donohue, Jr., principle investigator. R.W. Johnson Pharmaceutical Research Institute $58,680 1990.

28. Participant: Pharmacoepidemiology Research Program. State University of New York at Buffalo 1990-1995.

29. Comparison of Once Daily Zofenopril and Enalapril for the Treatment of Essential Hypertension with Renal Impaired Patients. Dr. Martin Bierman, principle investigator. E.I. Squibb & Sons, Inc. $35,962 1987-1988.

30. A Comparative Study of Oral RU965 and Erythromycin Ethylsuccinate (EES) in the Treatment of Patients with Infections Caused by Susceptible Bacteria. Dr. Jeffrey Brittan, principle investigator. Hoeschst-Roussell Pharmaceuticals, Inc. $24,000. 1985-1986.

31. A Comparative Crossover Trial of Cibenzoline and Quinidine in Patients with Premature Ventricular Beats. Dr. Syed Mohiuddin principle investigator. Hoffman-LaRoche Inc. $32,000 1984-1986.

Creighton University Press Release:

1. Pharmacy professor to publish on potential for drug to stave off HIV May 2016.

Abstracts: Peer Reviewed

1. Ased S, Vivekanandan R, Anthone J, Rayes H, Dhami J, Cabri A, Davids M, Amosson T, Macaraeg J, Fordjour A, Wilson J, Destache C. A Comparison of Staphylococcus aureus Bacteremia (SAB) Diagnosis and Management: Differences Between Academic and Community Hospital Settings. IDWeek. New Orleans, LA Oct 26-30, 2016 Accepted.

2. Anthone J, Cabri A, Walters RW, Destache C, Vivekanandan R. Impact of Pharmacist-Led Education on Prescribing Habits for Acute Treatment of Suspected Sexually Transmitted Infections (STIs) in an Academic Medical Center Emergency Department (ED). IDWeek. New Orleans, LA Oct 26-30, 2016 Accepted.

3. Mandal S and Destache CJ. Nanodrug-delivery system: Helping drugs to reach their targeted disease destination. Drug Delivery & Therapy World Congress Boston, MA. Aug 22-25, 2016. Accepted.

4. Mandal S, Destache CJ, Prathipati PK. Combination antiretroviral drug Loaded Nanoparticles: An efficacious nano-drug delivery system for prevention/treatment of HIV in a humanized (Hu-BLT) mouse model. Drug Delivery & Therapy World Congress Boston, MA. Aug 22-25, 2016. Accepted.

5. Shibata A, Bruck P, Pham R, Mandal S, Destache C. Development of dolutegravir combination nanoparticle fabrications for HIV prophylaxis. 2016 ASM-Microbe Conference. Boston, MA Jun 16-20, 2016.

6. Mandal S, Kang G, Yuan Z, Lu W, Prathipati PK, Li Q, Destache CJ. Combination antiretroviral (cARV) drug loaded nanoparticles (NPs) are efficacious in humanized (Hu-BLT) mice. (Abstract #SU-408) 2016 ASM-Microbe Conference. Boston, MA Jun 16-20, 2016. Presented as a poster.


17

7. Dhami JK, Anantha Narayanan M, Quirk SK, Destache CJ, Vivekanandan R. Multidrug-resistant Pseudomonas and continuous renal replacement therapy: A case report and review of Literature. (Abstract #10955) 2016 Am Thoracic Society annual meeting. San Francisco, CA May 18, 2016.

8. Destache CJ, Mandal S, Prathipati PK. TDF/EVG nanoparticle formulation: plasma pharmacokinetics in humanized mice. Conference on Retroviruses and Opportunistic Infections. (Abstract #16-1812) Boston, MA Feb 22-25, 2016. Presented as a poster.

9. Foral P, Anthone J, Horne J, Dobronski L, Syed J, Destache C, Vivekanandan R, Preheim L, Gorby G, Bittner M. Incorporating interprofessional practice education and motivational interviewing techniques in antimicrobial stewardship programs at two academic medical centers. (Abstract #P-428) 2015 IDWeek San Diego, CA.

10. Kaye KS, Destache C, Guevil DJ. Ceftaroline fosamil for the treatment of Gram-positive endocarditis CAPTURE study experience. 2015 Interscience Conference of Antimicrobial Agents and Chemotherapy. (Abstract #L-345) San Diego, CA.

11. Hoie E, Le S, Destache C. Use of fluconazole as prophylaxis for invasive Candida infections in preterm infants: a retrospective chart review. (#79E). 2015 Global Conference on Clinical Pharmacy. San Francisco, CA Oct 17-21, 2015.

12. Narayanan MA, Mansour G, Haddad T, Destache C, Vivekanandan R. Is there enough evidence for early surgery in infective endocarditis? A meta-analysis. 2015 American Thoracic Society Annual Meeting, Denver, CO May 15-20, 2015.

13. Date AA, Shibata A, Bruck P Rezich M, Madson C, Belshan M, Destache C. Polymeric nanoparticles of tenofovir disoproxil furmarate for HIV prophylaxis. (Abstract #T3100) 2014 American Association of Pharmaceutical Scientists Annual Meeting. San Diego, CA. Presented as a poster.

14. Destache CJ, Date AA, Zhe Y, Kang G, Lu W, Tso FY, Wood C, Li Q. Topical application of tenofovir DF nanoparticles prevents HIV-1 vaginal transmission in humanized-BLT mice. (Abstract #109) 2014 American College of Clinical Pharmacy Annual Meeting. San Antonio, TX. Presented as a poster.

15. Kaye K, Destache C, Cole P, Jandourek A, Friedland HD. Gram-positive infective endocarditis treated with ceftaroline fosamil: CAPTURE study experience. (Abstract #L-1735) 2014 Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington DC. Presented as a poster.

16. Destache CJ, Date AA, Zhe Y, Kang G, Lu W, Tso FY, Wood C, Li Q. Topical application of tenofovir DF nanoparticles prevents HIV-1 vaginal transmission in humanized-BLT mice. (#H-997) 2014 Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington DC. Presented as a poster.

17. Li Q, Tso FY, Kang G, Lu W, Li Y, Fan W, Destache CJ, Wood C. Early antiretroviral therapy prevents the establishment of HIV-1 infection in humanized-BLT mice. (#396) 2014 Conference on Retroviruses and Opportunistic Infections. Boston, MA. Mar 3-6, 2014. Presented as a poster.

18. Anthone J, Vivekanandan R, Mindru C, Ali K, Ali M, Horowitz E, Bittner M, Gorby G,


18

Destache C, Preheim L. Impact of an antimicrobial stewardship program (ASP) on antimicrobial usage and incidence of Clostridium difficile infections (CDI) at an academic teaching hospital. Abstract 41546 IDWeek San Francisco, CA Oct 2-5, 2013.

19. J. Long, C. Destache, M. Swanson, A. Date, J.V. Garcia. Thermosensitive gel delivery of rilpivirine nanoparticles (RPV NPs) prevents vaginal HIV-1 acquisition. Abstract MOPE141 International AIDS Society Meeting, Kuala Lumpur, Malaysia, June 30-July 3, 2013.

20. Rajca A, Li Q, Belshan M, Date A, Destache C. Thermosensitive vaginal gel containing PLGA-NRTI conjugate nanoparticles for HIV prophylaxis. Abstract T5.862. 2013 Nanotech Conference. Washington DC. May 12-16, 2013. Presented as a poster.

21. Cernik B, Foral P, Hrdy M, Destache C. Evaluating the appropriateness of an antimicrobial intravenous to oral conversion protocol compared to antimicrobial stewardship recommendations in a veterans affairs health care system. International Pharmaceutical Abstracts 2012. ASHP Midyear Clinical Meeting 46 (Dec). P3-157.

22. Date A, Shibata A, Goede M, Sanford B, DeBoer J, Belshan M, Destache CJ. Thermosensitive gel containing raltegravir + efavirenz loaded nanoparticles for HIV prophylaxis. Abstract 2737. 2012 American Association of Pharmaceutical Scientists Annual Meeting Chicago, IL.

23. Davis EM, Stang J, Foral PA, Baker TM, Destache C. Factors associated with early readmission of cardiothoracic surgical patients. American College of Clinical Pharmacy. Abstract 26438. Virtual Poster Symposium ACCP May 22-24, 2012.

24. Elsasser GN, Lorhan PS, Destache CJ. Identifying an optimal dose of vancomycin in morbidly obese patients. (Abstract 134). American College of Clinical Pharmacy Annual Meeting, Pittsburgh, PA October 2011.

25. Mohapatra S, Kadajji VG, Goede M, Destache CJ, Dash AK. Combination antiretroviral vaginal gels for prophylactic treatment of HIV-1. American Association of Pharmaceutical Scientists Annual Meeting, New Orleans, LA. November 2011.

26. Destache CJ, Knaak E, Elsasser GN, Cavalieri SM, Preheim LC. Antibiotic De-Escalation for ICU Pneumonia: What is the impact? (Abstract K-1454) 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL September 2011.

27. Destache CJ, Goede M, McMullen E, Pham A, Shibata A. Sub-cellular fractionation and confocal microscopy for nanoparticle antiretroviral drugs for HIV-infected cell lines. (Abstract 129) Protection from HIV: Targeted Intervention Strategies. A Keystone Conference. Whistler, British Columbia. Mar 20-25, 2011. Presented as a poster.

28. Davis WM, Foral PA, Baker TM, Herdzina AM, Destache C, Hardy KM. Identification of factors associated with early readmission of cardiothoracic surgical patients in a community hospital. Abstract 32 American College of Clinical Pharmacy 31st Annual Meeting, Austin, TX October 17-21, 2010.

29. Packard KA, Lenz TL, Destache CJ. A tool to teach heart failure guidelines and assess therapy in a cardiology rotation. American Association of Colleges of Pharmacy Annual Meeting, Seattle, WA. July 11-12, 2010.

30. Destache CJ, Belgum T, Shibata A, Dash A. In vivo levels of ritonavir, lopinavir, efavirenz


19

over time after intraperitoneal injection of antiretroviral PLGA nanoparticle. Abstract 115. American College of Clinical Pharmacy 30th Annual Meeting, Anaheim, CA. October 17-21, 2009. Presented as a poster.

31. Destache CJ, Lapic M, Cavalieri S. Comparison of treatment efficacy with metronidazole monotherapy or metronidazole + oral vancomycin for Clostridium difficile associated diarrhea (CDAD). Abstract 95. American College of Clinical Pharmacy 30th Annual Meeting, Anaheim, CA. October 17-21, 2009. Presented as a poster.

32. Destache CJ, Belgum T, Shibata A, Dash A. In vivo levels of ritonavir (RTV), lopinavir (LPV), efavirenz (EFV) over time after intraperitoneal (IP) injection of antiretroviral (AR) PLGA nanoparticle (NP). Abstract A1-1313. 49th Interconference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. September 12-15, 2009. Presented as a poster.

33. Elsasser GN, Kavan M, Destache CJ, Westerman G. Health science student’s experiences with gambling. 9th Annual NCRG Conference on Gambling and Addiction. Las Vegas, NV Nov 16-17, 2008.

34. Destache C, Belgum T, Elsasser GN, Christensen K, Shibata A. Ritonavir, lopinavir, and efavirenz-containing nanoparticles: in vitro release of anti-retroviral therapy (ART) Abstract F-128. 8th Conference on Retrovirus and Opportunistic Infections Boston, MA. Feb 3-6, 2008. Presented as a poster.

35. Dou H, Grotepas C, Boska MD, Destache C, Rabinow B, Gendelman HE. Antiretroviral nanoformulation for HIV-1 associated cognitive impairment. Abstract F-126. 8th Conference on Retrovirus and Opportunistic Infections, Boston, MA. Feb 3-6, 2008.

36. Opere CA, Zhao M, Destache CJ, Ohia SE. Role of prostanoids in the inhibitory effect of 8-isoprostaglandin E2 on bovine retinal glutamate and glycine levels, ex vivo. Abstract 2623. 2008 Association for Research in Vision and Ophthamology.

37. Stading J, Hermann J, Destache C, Faulkner M. Impact of pharmacist intervention on diabetes in an ambulatory care setting. American College of Clinical Pharmacy Annual Meeting. September 4-7, 2007, Denver CO.

38. Destache CJ, Chang JA, Malesker M, Schuller D, Morrow L. Efficacy of antimicrobials for acute exacerbation of chronic bronchitis episodes (Encore) American College of Clinical Pharmacy Annual Meeting September 4-7, 2007, Denver, CO. Abstract 128. Presented as a poster.

39. Davis EM, Christensen CM, Nystrom KK, Foral PM, Destache C. Nursing satisfaction of prefilled, disposable insulin pens compared to conventional insulin use in a community hospital (Encore). American College of Clinical Pharmacy Annual Meeting September 4-7, 2007.

40. Chang JA, Malesker M, Schuller D, Morrow L, Wichman T, Destache CJ. Efficacy of antimicrobials for acute exacerbation of chronic bronchitis episodes. American College of Chest Physicians Annual Meeting October 4-7, 2007, Chicago, IL.

41. Davis EM, Christensen CM, Nystrom KK, Foral PM, Destache C. Nursing satisfaction of prefilled, disposable insulin pens compared to conventional insulin use in a community hospital. American Diabetes Association 2007.


20

42. Zhao M, Liu H, Destache C, Zhan GL, Ohia SE, Opere CA. Regulation of endogenous glutamate levels by 8-isoPGF2α In rabbit retinae And vitreous humor, in vivo. 2007 Association for Research in Vision and Ophthalmology.

43. Opere CA, Zhao M, Liu H, Destache C, Ohia SE. Regulation of amino acid neurotransmitter levels by 8-isoPGE2 in bovine retinae, ex vivo 2007 Association for Research in Vision and Ophthamology. Abstract 4192. Presented as a poster.

44. Venkata C, Maleskar M, Destache C, Asham R, Venkateshiah SB. Comparison of dose of sedatives between day versus night shifts in ICU. 2007 American Thoracic Society annual meeting.

45. Boska M, Dou H, Liu Y, Destache C, Nelson J, Hahn T, Sneller H, Uberti M, Gendelman H. Superparamagnetic iron oxide-enhanced magnetic resonance imaging tracking of bone marrow-derived macrophage loaded anti-retroviral nanoparticles into brain regions with active murine HIV-1 encephalitis: Implications for treatment and monitoring of human disease. Abstract 366 2007 Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA.

46. Dou H, Destache CJ, Grotepas C, Trickler W, Chaubal M, Rabinow BE, Gendelman HE. Development of a macrophage-based paclitaxel nanoparticle delivery platform for brain tumors. 37th Society for Neuroscience. November 3-7, 2007, San Diego, CA.

47. C.A. Opere, H. Liu, M. Zhao, C.J. Destache, G. Zhan, S.E. Ohia. Effect of intravitreal 8-isoPGF2α on rabbit anterior uvea catecholamines, in vivo. Association for Research in Vision and Ophthalmology – Asia. March 2-7, 2007 Singapore, China.

48. Boska M, Dou H, Destache C, Nelson J, Poluektova L, Gorantla S, Rabinow B, Mosley RL, Gendelman HE. MRI and SPECT analyses for macrophage-based nanoparticle drug delivery: New avenues for improved monitoring of antiretroviral therapies. 2006 Garmon Conference.

49. Dou H, Destache CJ, Kibuule DC, Nelson JA, Morehead J, Boska M, Chaubal M, Werling J, Kipp J, Rabinow BE, Gendelman HE. Macrophage-based antiretroviral delivery: implications for HIV-1 associated dementia. 36th Society of Neuroscience. October 14-17, 2006 Atlanta, GA.

50. Dou H, Destache CJ, Kingsley J, Morehead J, Chauba M, Rabinow J, Gendelman HE. Macrophage-based antiretroviral delivery for HIV-1 associated dementia. 12th SNIP Conference Santa Fe, NM April 5-9, 2006.

51. Dou H, Destache CJ, Morehead JR, Mosley RL, Boska MD, Kingsley J, Gorantla S, Poluektova L, Nelson JA, Chaubal M, Werling J, Kipp J, Rabinow BE, Gendelman HE. A macrophage-based nanoparticle system for drug delivery: Pharmacokinetic and anti-viral activities in a murine model of HIV-1 infection. 15th World Congress of Pharmacology. Beijing CA July 2-7, 2006.

52. Nystrom, K, Kehrli J, Davis E, Christensen C, Foral P, Destache C. A review of chemotherapy induced febrile neutropenia management in a community hospital. ASHP Midyear Clinical Meeting 2006 Abstract P169E.

53. Christensen CM, Veit LM, Nystrom KK, Davis EM, Foral PA, Currier S, Wallingford B, Destache CJ. Early effectiveness of a post partum smoking cessation program. ASHP


21

Midyear Clinical Meeting 2006 Abstract P348R. 54. Davis EM, Christensen CM, Nystrom KK, Foral PM, Destache C. Nursing satisfaction of

prefilled, disposable insulin pens compared to conventional insulin use in a community hospital. ASHP Midyear Clinical Meeting 2006 P476E.

55. Elsasser GN, Hoie E, Destache CJ, Monaghan MS. Effect of lecture audio files on class attendance and examination performance. Am J Pharm Educ 2006;70:Article 65.

56. Dou H, Destache C, Morehead J, Mosley RL, Boska M, Kingsley J, Rabinow B, Gendelman HE. A macrophage nanoparticle system for anti-retroviral drug. 12th Annual Society for Neuroimmune Pharmacology meeting. Santa Fe, NM. 2006; Abstract TP-7.

57. Dou H, Destache C, Kingsley J, Morehead J, Chauba M, Rabinow J, Gendelman HE. Macrophage-based antiretroviral delivery for HIV-1 associated dementia. 12th Annual Society for Neuroimmune Pharmacology meeting. Santa Fe, NM. 2006; Abstract TP-8.

58. Dou H, Destache C, Nelson J, Poluektova L, Gorantla S, Boska M, Rabinow B, Mosley RL, Gendelman HE. Macrophage nanoparticle delivery system for anti-retroviral medicines: Treatment of HIV-1 infection in the nervous system & other viral reservoirs. Acta Pharmacologica Sinica 2006;27 (Suppl 1):28.

59. Dou H, Destache C, Mosley RL, Boska M, Rabinow B, Gendelman H. A macrophage-based nanoparticle system for drug delivery: Pharmacokinetic and anti-viral activities in a murine model of HIV-1 infection. Acta Pharmacologica Sinica 2006;27 (Suppl 1):272.

60. Dou H, Destache CJ, Morehead JR, Losley RL, Boska MD, Kingsley J, Gorantla S, Poluektova L, Nelson JA, Chaubal M, Werling J, Kipp J, Rabinow BE, Gendelman HE. A macrophage-based nanoparticle system for drug delivery: Pharmacokinetic and anti-viral activities in a murine model of HIV-1 infection. 15th World Congress of Pharmacology. Beijing, China July 2-7, 2006.

61. Dou H, Destache CJ, Morehead JR, Mosley, R, Boska MD, Kingsley J, Gorantla S, Plouetova L, Nelson JA, CHaubal M, Werling J, Kipp J, Rabinow BE, Gendelman HE. Pharmacokinetics, immune, and anti-viral resonses of nanoparticle indinavir in a murine model of HIV-1 encephalitis. J Neuroimmun 2006;178(Suppl 1):70.

62. Elsasser GN, Frey D, Goodman M, Destache CJ. Venous thromboembolism prophylaxis: experience with a preprinted risk assessment and prophylaxis order form in a population of family medicine inpatients. Pharmacotherapy 2006;26:636.

63. CJ Destache, CA Opere, H Lui, M Zhao, G Zhan, SE Ohia. Effect of 8-Iso-PGE2 on rabbit anterior uveal neurotransmitters in vivo. Association for Research in Vision and Ophthalmology Annual Meeting. 2006; Abstract 2614/B772. Presented as a poster.

64. CA Opere, M Zhao, H Lui, CJ Destache, R Zeyssig, EM Monjok, GE Kouamou, SE Ohia. Regulation of mammalian retinal neurotransmitter levels by 8-iso-PGF2α and 8-iso-PGE2. Association for Research in Vision and Ophthalmology Annual Meeting. 2006; Abstract 2613/B772.

65. M Zhao, CA Opere, H Liu, CJ Destache, G Zhan, SE Ohia. Regulation of rabbit retinal and vitreous humor neurotransmitter levels by 8-Iso-PGF2α in vivo. Association for Research in Vision and Ophthalmology Annual Meeting. 2006; Abstract 3770/B413.


22

66. H Liu, M Zhao, CJ Destache, G Zhan, SE Ohia, CA Opere. Effect of 8-Iso-PGE2 on catecholamine levels in rabbit retina and vitreous human, in vivo. Association for Research in Vision and Ophthalmology Annual Meeting. 2006; Abstract 2616/B775.

67. Boska M, Dou H, Destache C, Nelson J, Poluektova L, Gorantla S, Rabinow B, Mosley RL, Gendelman H. Development of a macrophage nanoparticle delivery system for Anti-retroviral medicines: Implications for treatment of HIV-1 infection in the nervous system and other viral reservoirs. International Society for Magnetic Resonance in Medicine 2005.

68. Gendelman HE, Benner E, Kipnis J, Destache C, Thomas MP, Nelson J, Shlyakhtenko LS, Lyubchenko YL, Laurie C, Reynolds A, Boska M, Mosley RL. Immunomodulation in experimental models of Parkinson’s disease. 9th International Symposium on Parkinson Research. 2005.

69. Dou H, Destache CJ, Nelson JA, Poluektova L, Gorantla S, Kingsley J, Boska M, Chaubal M, Werling J, Rabinow BE, Mosley RL, Gendelman HE. A bone-marrow derived macrophage nanoparticle delivery system for delivery of anti-retroviral medicine: implications for treatment of HIV-1 infection and viral encephalitis. Dohlman Conference, Paris, FR November 2005.

70. Destache CJ, Knudsen DS. Impact of time to antibiotic administration (TAA) on hospitalization length for community-acquired pneumonia (CAP). Pharmacotherapy 2005;25:1457. Presented as a poster.

71. Mosley RL, Gorantla S, Dou H, Destache CJ, Nelson J, Kingsley J, Poluektova L, Boska M, Chaubal M, Werling J, Kipp J, Rabinow B, Gendelman HE. Non-invasive real time image analysis of leukocyte trafficking under steady-state and inflammatory conditions. Keystone Symposium on Leukocyte Trafficking. March 2005.

72. Gendelman HE, Gorantla S, Nelson J, Kingsley J, Destache CJ, Chaubal M, Werling J, Kipp J, Poluektova L, Rabinow B, Boska M, Mosley RL, Dou H. Indinavir nanosuspensions: A platform for macrophage-based anti-retroviral delivery. 2004 Conference on Retrovrius and Opportunistic Infections.

73. Boska M, Lewis T, Destache C, Benner E, Nelson J, Uberti M, Mosley R and Gendelman H. Quantitative 1H Magnetic Resonance Spectroscopic Imaging Determines Therapeutic Immunization Effectiveness in an Animal Model of Parkinson’s Disease. CNS Inflammation: Mechanisms, Consequences, Therapeutic Strategies. Keystone Symposium 2004.

74. Gendelman HE, Dou H, Limoges J, Ellison B, Destache CJ, Rabinow B. Indinavir nanosuspensions and macrophage-based drug delivery: Implications for anti-retroviral therapy for HIV-1 encephalitis. Society for Neuroscience 2004 Abstract 446.13.

75. Destache CJ. Assessing Current Threats: Natural and Man-Made. 38th Midyear Clinical Meeting of the American Society for Health-System Pharmacists. New Orleans, LA. December 9, 2003.

76. Benner EJ, Mosley RL, Jackson-Lewis V, Destache CJ, Lewis T, Nemechek C, Przedborski S, Gendelman HE. Copaxone immunization protects dopaminergic neurons in an MPTP mouse model of Parkinson’s disease. Society for Neuroscience 2003; Abstract 401.1.

77. Carlson KA, Schellpeper CN, Biskup TM, Mack AL, Kadiu I, Destache CJ, Gendelman HE.


23

Proteomic Fingerprints from HIV-1-infected Monocyte-derived Macrophages Parallel the Course of Viral Replication: Relevance to HIV-1-Asociated Dementia. 5th International Symposium on Neurovirology. 2003.

78. Lenz TL, Destache CJ, Hilleman DE, Faulkner MA, Monaghan MS, Arouni AA. Pharmacokinetic interaction between warfarin and ginseng. American College of Clinical Pharmacy annual meeting. Pharmacotherapy 2003;23:Abstract 322.

79. Gendelman HE, Destache CJ, Zelivyanskaya ML, Nelson JA, Boska MD, Biskup TM, Carlson KA, Nemechek CR, Benner EJ, Mosley RL. Neuroimaging and proteomic tracking of neurodegeneration following MPTP intoxication of mice. New York Academy of Sciences “Parkinson’s Disease: The Life Cycle of the Dopamine Neuron” Meeting. Rochester, NY. September 18-20, 2002.

80. Destache CJ and Chock A. Outpatient antibiotics in acute exacerbation of chronic bronchitis (AECB) patients admitted to the hospital. Chest 2002;122(Suppl):161S.

81. Elsasser GN, Daher P, Destache CJ, Jones JJ, Frey DJ. Sustained-release buspurion or placebo in adolescents for smoking cessation. American Society for Prevention of Drug Abuse Meeting Savannah, GA. February 21-24, 2002.

82. Destache CJ, Pakiz CB, Larsen C, Owens H, Dash AK. Levofloxacin penetration into CSF using microdialysis in a rabbit model of pneumococccal meningitis. Pharmacotherapy 2000;20:Abstract 128E. Presented as a poster.

83. Destache CJ, Pakiz CB, Larsen C, Owens H, Dash AK. Levofloxacin penetration into CSF using microdialysis in a rabbit model of pneumococccal meningitis. J Pharm Sci 1999; Abstract #3381.

84. Owens HM, Destache CJ, Pakiz CB, Larsen C, and Dash AK. Study of the Blood Brain Barrier Permeability Characteristics of Various Antibiotics in an Experimental Rabbit Meningitis Model. J Pharm Sci 1998; Abstract #3723.

85. Veligandla S, Gorby G, Veligandla H, Destache C. Clostridium perfringens bacteremia associated with tongue bit. Nebraska Medical Society Research Conference. October 1999; Abstract #34.

86. Pong A, Harrison CJ, Siedel TW, Needleman HW, Jirka J, Awad K, Cothran DL, Ohri L, Destache CJ. An Improved Regimen of Gentamicin Dosing in Neonates. 36th Infectious Diseases Society of America meeting, November 1998; Abstract 257-Sa. Infectious Diseases Society of America.

87. Streetman DS, Nafziger AN, Destache CJ, Bertino JS, Jr. Individualized Pharmacokinetic Monitoring (IPM) Results in Less Aminoglycoside-Associated Nephrotoxicity (AAN). 38th Interscience Conference on Antimicrobial Agents and Chemotherapy September 1998; Abstract A-79. American Society for Microbiology.

88. Young J, Mimuro D, Tejani A, Destache CJ. Length of Hospitalization in Community-Acquired Infections Associated with Appendicitis. Pharmacother 1998; Abstract 78.

89. Dickes MT, Ho J, Destache CJ. Implementation of a Vancomycin Order Form on Vancomycin Use in the Hospital. Pharmacother 1998; Abstract 77.

90. Destache CJ, Pakiz CB, Larsen C, Dash AK. Nitric oxide (NO) concentrations in S.


24

pneumoniae meningitis: correlation to cytopathology. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy September 1997;Abstract B-068 American Society for Microbiology. Presented as a poster.

91. Destache CJ, Pakiz CB, McConnell S, Cavalieri SJ. Effect of penicillin (PCN) susceptibility on morbidity and mortality in S. pneumoniae infections. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology. September 1997;Abstract K-089. Presented as a poster.

92. Destache CJ, Pakiz CB, Larsen C, Dash AK. Cytopathology and nitric oxide (NO) concentrations in an experimental model of S. pneumoniae (STP) meningitis. J Pharm Sci 1997; Abstract #1524.

93. Destache CJ, Pakiz CB, Larsen C, Dash AK. Nitric oxide (NO) concentrations in S. pneumoniae meningitis: correlation to cytopathology. Pharmacother 1997;17:1132. Presented as a poster.

94. Destache CJ, Huntington B, Pakiz CB. Effect of 10% pooled human serum (PHS) on microbiological killing of encapsulated organisms by azithromycin. American Society for Microbiology Annual Meeting 1997;Abstract A-143. Presented as a poster.

95. Destache CJ, Shinn B, Elsasser GN. Assessment of Pharmaceutical Intervention in Community-Acquired Pneumonia. Pharmacother 1995; 15:100. Presented as a poster.

96. Danekas P, Massoomi F, Destache CJ. Creatinine clearance estimations in obese patients. Pharmacother 1995;15:121.

97. Dewan N, Destache CJ, O’Donohue WJ, Jr. Campbell JC, Angelillo VA. Antibiotic Choice and Office Visits for Acute Exacerbation of Chronic Bronchitis. Chest 1994;106(Suppl):161S.

98. Ostrom N, Prenner B, Destache CJ, Orsulak P, Findlay J. Evaluation of a "Near-Patient" Assay System for Theophylline. Poster presentation at the American College of Allergy and Immunology Annual Meeting November 12, 1993.

99. Destache CJ, Massoomi F, Vanden Bosch A, Bertoni J, Steg R. Comparison of Predicting Phenytoin Concentrations with Bayesian (B) and Martin-Tozer (M-T) Methods. Pharmacother 1992;12:250.

100. Lucas BD, Mohiuddin SM, Stoysich AM, Destache CJ, Hunter CV, Stading JA, Hilleman DE. Assessment of a Possible Pharmacokinetic Interaction Between Diltiazem and Warfarin. Pharmacother 1992;12:259.

101. Lile JA, Destache CJ. Predictive Modeling for Aminoglycoside Nephrotoxicity. Midwest Residency Conference. Minneapolis, MN. April 1991.

102. Kosirog J, Rospond RM, Destache CJ, Hall PD. Validation of Aminoglycoside Population Parameters in Cancer Patients. Pharmacother 1991;11:105.

103. Gannon JM, Mohiuddin SM, Destache CJ, Stoysich AM, Hilleman DE. Interaction Between Theophylline and Mexiletine. Clin Pharmacol Ther 1991;49:142. Presented as a poster.

104. Hilleman DE, Mohiuddin SM, Destache CJ, Stoysich AS, Larsen KE, Sketch MH. Cost-Effectiveness of Early versus Late Initiation of Warfarin during Heparin Therapy.


25

Pharmacother 1990;10:246. 105. Mohiuddin SM, Hilleman DE, Destache CJ, Stoysich AS, Larsen KE Sketch MH. Cost-

Effectiveness of Early versus Late Initiation of Warfarin during Heparin Therapy. Chest 1990;98(Suppl 2):6S.

106. Hilleman DE, Mohiuddin SM, Destache CJ, Stoysich AS, Larsen KE. Pharmacokinetic and Pharmacodynamic Evaluation of Continuous Infusion Tocainide in Acute Myocardial Infarction. J Clin Pharmacol 1990;30:845.

107. Stoysich AS, Mohiuddin SM, Destache CJ, Nipper HC, Maleskar MA, Hilleman DE. Bioavailability of Encainide and Food. J Clin Pharmacol 1992;32:833.

108. Andersen KM and Destache CJ. Predictive performance of Bayesian versus Wagner methods for Neonatal Gentamicin Concentrations. 24th American Society of Hospital Pharmacists Midyear Clinical Meeting, Atlanta, GA, December 7, 1989. Presented as a poster.

109. Destache CJ, Meyer SM, Andersen KM, Padomek MT. Does Accepting Pharmacokinetic Recommendations Impact Hospitalization? A Cost-Benefit Analysis. 24th American Society of Hospital Pharmacists Midyear Clinical Meeting, Atlanta, GA. December 4, 1989. Presented as a poster.

110. Hilleman DE, Mohiuddin SE, Destache CJ, Makesker MA, Dean RR. Pharmacokinetic and Tolerance Evaluation of Acetisomide in Healthy Volunteers. J Clin Pharmacol 1989;29:843.

111. Destache CJ, Meyer SM, Bittner MJ, Hermann KG. Impact of a Clinical Pharmacokinetic Service on Patients Treated with Aminoglycosides: A Cost-Benefit Analysis. Pharmacother 1989;9:181. Presented as a poster.

112. Destache CJ, Thibodeau P, Hilleman DE, Mohiuddin SM. Predictive Performance of a Bayesian Lidocaine Program in Acute or Chronic Arrhythmia Patients. Pharmacother 1989;9:176.

113. Rospond RM, Destache CJ, Mailliard J, Johnson PJ, Boman B. Evaluation of Aminoglycoside Pharmacokinetics in Hematology-Oncology Patients. Pharmacother 1989;9:186.

114. Destache CJ, Meyer SM, Ortmeier BG, Padomek MT. Impact of a Clinical Pharmacokinetic Service on Patients Treated with Aminoglycosides for Gram-Negative Infections. 22nd American Society of Hospital Pharmacists Midyear Clinical Meeting, Atlanta, GA. December 6-10, 1987. Presented as a poster.

115. Hilleman DE, Mohiuddin SM, Destache CJ. A Comparative Crossover Trial of Cibenzoline and Quinidine in Ventricular Arrhythmias. Clin Res January, 1985.

116. Destache CJ, Hilleman DE, Mohiuddin SM. Lidocaine-Induced Second Degree Mobitz Type II Heart Block. Drug Intelligence and Clinical Pharmacy, 1984;18:498. Presented as a poster.

Book Chapter 1. Destache CJ, Meyer SM, Bittner MJ, Hermann KG. Impact of a Clinical Pharmacokinetic


26

Service on Patients Treated with Aminoglycosides: A Cost-Benefit Analysis. Recent Developments in Therapeutic Drug Monitoring. Sunshine IC. ed., Marcel Dekker, Inc., New York, New York, 1992 pg. 159-164.

2. Gendelman HE, Destache CJ, Zelivyanskaya ML, et al. Neuroimaging and proteomic tracking of neurodegeneration in MPTP-treated mice. Parkinson’s Disease The Life Cycle of the Dopamine Neuron. Federoff HJ, Burke RE, Fahn S, Fiskum G. eds. Annuals of the New York Academy of Sciences. Vol 991 2002; pg 319-321.

3. Destache CJ. Brain as an HIV Sequestered Site: Use of Nanoparticles as a Therapeutic Option. Progress in Brain Research (Volume 180, Chapter 12). Elsevier Academic Press. 2010.

Continuing Education Monograph 1. Amdsen G and Destache CJ. Pharmacoeconomic Considerations in the Treatment of Lower

Respiratory Tract Infections. Scientific Exchange Inc. November 1996;1-24. Letters to the Editor: 1. The 10 x 20 initiative – response from the Society of Infectious Diseases Pharmacists. Clin

Infect Dis 2010;51:753.

PRESENTATIONS: International Oral Presentations: 1. Cost-Benefit of a Clinical Pharmacokinetic Service for Aminoglycoside Therapy. Invited

presentation at the Fourth International Congress on Therapeutic Drug Monitoring and Clinical Toxicology. Vienna, Austria. September 6, 1995.

2. The Use of Therapeutic Drug Monitoring in Pharmacoeconomics. Invited presentation at the Third International Congress on Therapeutic Drug Monitoring and Clinical Toxicology. Philadelphia, PA. May 28, 1993.

3. Therapeutic Drug Monitoring -- Saving Lives and Money. Invited presentation at the Australian Society of Clinical and Experimental Pharmacology and Toxicology University of South Wales, Sidney, Australia. December 7, 1992.

4. Therapeutic Drug Monitoring -- A Pharmacists Perspective. Invited presentation at the Sixth Annual Clinical Pharmacokinetics Society of Great Britain. Royal Pharmaceutical Society Headquarters, London, England. November 9, 1992.

5. Impact of a Clinical Pharmacokinetic Service on Patients Treated with Aminoglycosides: A Cost-Benefit Analysis. Invited presentation at the Second International Congress on Therapeutic Drug Monitoring and Clinical Toxicology. Barcelona, Spain, October 8, 1990.

National Oral Presentations:

1. Antiretroviral nanoparticles for HIV infection. Presented at the 2014 ACCP Annual Meeting, Austin, TX October 14, 2014.

2. Cerebrospinal fluid penetration and pharmacokinetics of anti-infective agents. Presented at


27

the 2013 AAPS Annual Meeting and Exposition, San Antonio, TX November 13, 2013. 3. In vivo levels of ritonavir, lopinavir, efavirenz over time after intraperitoneal injection of

antiretroviral PLGA nanoparticle. Part of the Great 8 abstracts presented at the 30th American College of Clinical Pharmacy meeting. Anaheim, CA October 19, 2009.

4. Assessing Current Threats: Natural and Man-Made. 38th Midyear Clinical Meeting of the American Society for Health-System Pharmacists. New Orleans, LA. December 9, 2003.

5. Statistics in Review. 10th Annual Pediatric Pharmacy Advisory Group Meeting. St. Louis, MO October 12 and 13, 2001.

6. Optimizing Economic Outcomes in Respiratory Tract Infections. Satellite Symposium to the American College of Clinical Pharmacy annual meeting, Los Angeles, CA November 5, 2000.

7. Nitric Oxide Concentrations in S. pneumoniae Meningitis: Correlation to Cytopathology. Presented at the Society of Infectious Diseases Pharmacists Annual Meeting Toronto, Canada September 27, 1997.

8. Economic Evaluation of Clinical Pharmacy Services. Presented at the 1996 American Society of Health System Pharmacists Annual Meeting, San Diego, CA. June 6, 1996.

9. Economic Evaluation of Clinical Pharmacy Services. Presented at the 1995 American Society of Health System Pharmacists Midyear Clinical Meeting, Las Vegas, NV. December 5, 1995.

10. Moderator for Specialty Practice Group in Clinical Pharmacokinetics at the 1993 Midyear Clinical Meeting of the American Society of Hospital Pharmacists, Atlanta, GA. December 6, 1993. Topic: "Reimbursement Issues for Clinical Pharmacokinetics."

11. “Clinical Pharmacokinetics” at the Career Consultation Section of the 24th American Society of Hospital Pharmacists Midyear Clinical Meeting, Atlanta, GA. December 6, 1989.

12. Does Accepting Pharmacokinetic Recommendations Impact Hospitalization? A Cost-Benefit Analysis. Platform presentation at the American Society of Hospital Pharmacists 24th Midyear Clinical Meeting, Atlanta, GA. December 7, 1989.

13. Impact of a Clinical Pharmacokinetic Service on Patients Treated with Aminoglycosides: A Cost-Benefit Analysis. Platform presentation at the 10th Annual American College of Clinical Pharmacy Meeting, Kansas City, MO. August 8, 1989.

14. Inpatient Temperature Monitoring during the Transition of IV to Oral Antibiotics in the Treatment of Pyelonephritis: Is it necessary? Platform presentation at North American Primary Care Research Group Meeting, Seattle, WA. April 15, 1985.

Regional Oral Presentations: (29 total) 1. Exploring antiretroviral nanomedicines for treatment and prevention of HIV infection. Invited presentation Tulane National Primate Research Center. September 16, 2016. 2. Natural polyphenols: Use against viral STI. Northwest Regional Chemical Society, Anchorage, AK June 28, 2016. 3. Development of a nanoparticle-based thermosensitive vaginal gel for HIV prevention. 47th


28

American Chemical Society Regional Meeting. Omaha, NE October 25, 2012. 4. Evaluation of nanomedicine for HIV treatment and prevention. Distinguished Lecture Series. Texas Tech Center of Excellence in Infectious Diseases, Texas Tech University Health Sciences Center, El Paso, TX January 24, 2014. 5. Topical tenofovir nanoparticle application prevents HIV-1 vaginal transmission in humanized-BLT mice. Nebraska Center for Virology Annual retreat, Nebraska City, NE March 23, 2014. 6. HIV Treatment Up-date and Treatment of Hepatitis C. Alaska Pharmacists Association annual meeting. April 4-6, 2014. 7. Rapid Viral Respiratory Pathogen Identification. MEDS symposium. Omaha, NE October 29, 2014. 8. New Antimicrobials. Creighton University Infectious Diseases Symposium. Omaha, NE April 23, 2016. Creighton University Oral Presentations (34 total) 1. “Antiretroviral Nanoparticles for HIV-1 Treatment and Prevention” Biomedical Sciences Department, Creighton University September 27, 2016. 2. “Exploring antiretroviral nanomedicines for treatment and prevention of HIV infection”. Invited presentation Department of Pharmacy Sciences, School of Pharmacy, Creighton University. September 20, 2016.

UNIVERSITY AND COMMUNITY SERVICE Creighton University Committee: Member: Institutional Biosafety Committee 2009 – Present Research and Scholarship Task Force 2012

Institutional Review Board (Human Studies) 1997 – 2003 2005 - 2008

Faculty Council 1998 - 2000 Academic Council 1998 - 2000 School of Pharmacy & Allied Health Committees: Member: Non-Traditional Doctor of Pharmacy Degree

Admissions Committee 1994-1998 Grade Appeals Committee 1992-1993 Executive Committee 2014-2016

1989-1990 1993-1994 Scholarship and Award Committee 1988-1992 Rank & Tenure Committee 2003-2006; 2015-2017 Chair: Rank & Tenure Committee 2004-2006 PEP Committee 2003-2004 Student Advisor 1990 to present: 100 students Chair: Grade Appeals Committee 1990-1991


29

Graduate Student Committee:

Heather Owens, Pharm. D., M. S. 1994 - 1995 Min Zhao, M. D., Ph. D. 2006 - 2008 Bridget Sanford, M. S. 2011 – 2012

Ashley Holec (Co-Primary advisor) 2016 – Present Catholic Health Initiative: Member, Antimicrobial Stewardship Committee 2014 – Present Member, Ebola Preparedness Committee 2014 – Present Member, Pharmacy & Therapeutics Committee 2015 – Present Professional Service: Society of Infectious Diseases Pharmacists 1994 – Present Nominations Committee 1996-1997 Awards Committee 1997-1998 Publications Committee 2000-2001 Research Committee 2004-2005 Political Action Committee 2009-2011 Membership Committee 2014-2015 American College of Clinical Pharmacy Credentialing Committee for Fellow status 2009-2013 ACCP ID-PRN 1994 – Present Publications Committee 2016-2017 ACCP HIV-PRN 2010 – Present Research Committee 2016-2017 American Society of Hospital Pharmacists Chair, Specialty Practice Group in Clinical Pharmacokinetics 1993-1994 American Association of Colleges of Pharmacy 2010-Present American Society for Microbiology 1992-Present Manuscript Reviewer: The Annuals of Pharmacotherapy; Pharmacotherapy; Clinical Infectious Diseases; Antimicrobial Agents and Chemotherapy; Journal of Antimicrobial Chemotherapy; Clinical Pharmacology and Therapeutics; European Journal of Pharmaceutics; Journal of Physical Chemistry, Antiviral Research; Current HIV Research; Colloids and Surfaces B: Biointerfaces Reviewer for American College of Clinical Pharmacy Annual Meeting 1998 - Present Reviewer for American Association of Pharmaceutical Scientists (PPDM Section) Annual Meeting 2012 Editorial Board: PharmacoEconomics 2002 - 2012


30

Expert Reviews in Anti-Infective Therapy 2009 – Present Therapeutic Delivery 2009 - Present Reviewer for National Science Foundation, ECCS Group 2009 Reviewer for Recovery Act Limited Competition, National Institutes of Health (RC4) 2010 Ad hoc NIH Special Emphasis Review ZAI1-JBS-A-M1 2011 Ad hoc reviewer for NIH Center for AIDS Research (CFAR) 2011 Ad hoc reviewer for NIAID RFA-AI-11-016 2011 Ad hoc reviewer for NIAID AZI1 JKB-M (J1) 1 2011 Ad hoc reviewer for NIAID ZAI1-UKS-A-J1 2012 Ad hoc reviewer for NIAID SBIR Contract Proposals 2013 Ad hoc reviewer for NIAID-DAIDS-NIHAI2013170 2013 Ad hoc reviewer for NIAID-DAIDS-ZRG1 AARR-K 2014 Ad hoc reviewer for NIAID-DAIDS-ZAI1-JRR-A-J3 2014 Ad hoc reviewer for NIAID-DAIDS-AZI1 JBS-A (M1) 2 2015 Ad hoc reviewer for NIAID AARR-K (57) R 2015 Ad hoc reviewer for NIAID ZAI1 JKB-A (J2) 1 2015 Ad hoc reviewer for NIAID ZRG1 AARR-D (51) R 2016 Ad hoc reviewer for NIAID ZRG1 AARR-M (54) 2016 AWARDS: Creighton University School of Pharmacy & Allied Health Professions Scholarly Achievement Award April 2012 Member, Alpha Sigma Nu Creighton University Jesuit Honor Society February 2011 Elected as Fellow, American College of Clinical Pharmacy 2002

Creighton University School of Pharmacy & Allied Health Professions Scholarly Achievement Award 1993-1994

Patents: US Patent No. 13/132,442 Nanoparticles and Methods of Use 30 September 2014 International Patent Application No. PCT/US2009/067724 US Provisional Patent 61/697,083 December 2009 International Patent Cooperation Treaty (PCT) Polymeric Nanoparticles in a Thermosensitive Gel for Coital-Independent Vaginal Prophylaxis of HIV WO 2014/039185 A1 13 March 2014 Encapsulation of hydrophilic antiretroviral drugs in nanocarriers US Patent 14/792,288 31 December 2015


31

REFERENCES Available upon request

Documents

CURRICULUM VITAE CHRISTOPHER J. DESTACHE PERSONAL · CURRICULUM VITAE CHRISTOPHER J. DESTACHE PERSONAL ... Fletcher CV, Li Q. Topical ... Ahmad I, Zhao X, Parameswaran S,